Akebia Therapeutics, Inc.
Since our founding in 2007, we’ve put tenacity and innovation to work to develop unique therapeutics that have the potential to set new standards of care for people living with kidney disease. We have emerged as a leader with deep roots in the renal community. Today, we are a fully integrated biopharmaceutical company with both an experienced nephrology-focused commercial team and a robust development organization. We have a commercial product approved and marketed in the United States, Japan and Taiwan, and a late-stage product candidate. Our lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Nationally (across the country)
- Year Founded:
- 2007
About Us
We have a commercial product approved and marketed in the United States, Japan and Taiwan, and a late-stage product candidate. Our lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). Following the completion of our global Phase 3 clinical development program for vadadustat, we now have filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for U.S. regulatory approval for vadadustat for the treatment of anemia due to CKD in adult patients on dialysis and adult patients not on dialysis.
Vadadustat is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for use outside of Japan.
We know that big change is possible when we work together, within Akebia and well beyond our four walls. We collaborate with partners around the globe, members of the medical and biopharmaceutical communities, as well as patient organizations.